Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KLKB1 | P03952 | 7/20 | 0.40 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21028247 | 0.90 | TSHR (0.44) | TSHRMAPK1TDP1NOTUMKLKB1 | |
| SCHEMBL21027812 | 0.82 | MAPT (0.47) | TSHRMAPK1TDP1MAPTKLKB1 | |
| SCHEMBL19780290 | 0.81 | KLKB1 (0.43) | KLKB1MAP4K1 | |
| SCHEMBL19780503 | 0.80 | KLKB1 (0.45) | KLKB1MAP4K1 | |
| SCHEMBL6980080 | 0.78 | MAPT (0.57) | TSHRMAPK1TDP1NOTUMMAPT | |
| SCHEMBL554212 | 0.78 | KLKB1 (0.44) | TDP1KLKB1MAP4K1 | |
| SCHEMBL21177523 | 0.78 | KLKB1 (0.46) | KLKB1MAP4K1 | |
| SCHEMBL19780416 | 0.77 | KLKB1 (0.46) | KLKB1MAP4K1 | |
| SCHEMBL19780293 | 0.76 | KLKB1 (0.46) | KLKB1MAP4K1 | |
| SCHEMBL19780289 | 0.75 | KLKB1 (0.43) | KLKB1MAP4K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10781200-B2 | Therapeutic inhibitory compounds | ATTUNE PHARMACEUTICALS, INC. (US) | 2020-09-22 | — | — | US | disclosed |
| US-10301284-B2 | Therapeutic inhibitory compounds | LIFESCI PHARMACEUTICALS, INC. (BB) | 2019-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10781200-B2 | Therapeutic inhibitory compounds | KLKB1, SERPINB1, SERPINE1 | TSHR 4687/4885MAPK1 1148/4885TDP1 3331/4885 |
| US-10301284-B2 | Therapeutic inhibitory compounds | KLKB1, SERPINB1, SERPINE1 | TSHR 4687/4885MAPK1 1148/4885TDP1 3331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.